List of Excipients in Branded Drug IMURAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sebela Pharmaceuticals Inc	IMURAN	azathioprine	54766-590	LACTOSE
Sebela Pharmaceuticals Inc	IMURAN	azathioprine	54766-590	MAGNESIUM STEARATE
Sebela Pharmaceuticals Inc	IMURAN	azathioprine	54766-590	POVIDONE
Sebela Pharmaceuticals Inc	IMURAN	azathioprine	54766-590	STARCH, POTATO
Sebela Pharmaceuticals Inc	IMURAN	azathioprine	54766-590	STEARIC ACID
Prometheus Laboratories Inc	IMURAN	azathioprine	65483-590	LACTOSE

Imuran Excipient Strategy and Commercial Opportunities for Azathioprine

Last updated: September 16, 2026

Imuran is the original brand of azathioprine, an oral immunosuppressant and purine antimetabolite used in organ transplantation and autoimmune diseases. Its active-ingredient, composition-of-matter, and original product patents are long expired. Commercial opportunity therefore depends on differentiated formulation, reliable supply, patient usability, and regulatory execution rather than conventional exclusivity around azathioprine itself.

The strongest formulation opportunities are lactose-free tablets, pediatric and geriatric liquids, low-dose flexible products, improved dissolution systems, and hospital-oriented injectable presentations. The main technical constraints are azathioprine’s low aqueous solubility, dose-related toxicity, narrow therapeutic use, chemical instability under some conditions, and the need for careful manufacturing controls.

What is Imuran and how is azathioprine used?

Imuran contains azathioprine, a prodrug that is converted to active thiopurine metabolites. The drug suppresses immune-cell proliferation and has regulatory uses in transplant medicine and selected inflammatory or autoimmune conditions.

Attribute	Imuran and azathioprine
Brand	Imuran
Active ingredient	Azathioprine
Drug class	Immunosuppressant; purine antimetabolite
Common oral strength	50 mg
Principal uses	Renal transplantation and selected autoimmune or inflammatory disorders
Original developer	Burroughs Wellcome
FDA regulatory status	Legacy approved product; generic azathioprine products are available
Current exclusivity	No meaningful remaining market exclusivity for the active ingredient
Primary dosage forms	Film-coated tablets; injectable presentations in selected markets
Key safety controls	Myelosuppression, hepatotoxicity, infection risk, malignancy risk, TPMT and NUDT15-related toxicity concerns

The FDA-approved label warns about severe bone-marrow suppression, serious infections, hepatotoxicity, malignancies, and hypersensitivity. It also identifies increased toxicity risk in patients with reduced TPMT or NUDT15 activity and in patients receiving certain interacting drugs, including allopurinol and febuxostat.[1]

What excipients are used in Imuran tablets?

The U.S. Imuran tablet labeling identifies a conventional excipient system based on lactose, maize starch, magnesium stearate, and film-coating materials. The listed coating components include hypromellose, macrogol, titanium dioxide, and iron oxide yellow.[2]

Excipient function	Imuran-type material	Formulation role
Diluent	Lactose	Adds tablet mass and supports direct compression or granulation
Disintegrant or binder	Maize starch	Supports tablet breakup and mechanical strength
Lubricant	Magnesium stearate	Reduces sticking and ejection force
Film former	Hypromellose	Provides tablet coating and handling protection
Plasticizer or coating aid	Macrogol	Improves coating flexibility
Opacifier	Titanium dioxide	Supports coating opacity and appearance
Colorant	Iron oxide yellow	Product identification and visual differentiation

The formulation is commercially effective but leaves room for product differentiation. Lactose creates an opportunity for a lactose-free version. Starch and magnesium stearate are standard, low-cost materials, so replacing them only creates value when the change improves manufacturability, dissolution, stability, swallowability, or patient access.

Excipients can vary by manufacturer and jurisdiction. A generic azathioprine product does not need to reproduce the complete Imuran excipient profile, but it must meet applicable quality, bioequivalence, stability, and labeling requirements.

What excipient strategy best fits an azathioprine product?

The most defensible strategy is to use excipients to solve a defined patient or manufacturing problem. A reformulation that changes color, filler, or coating without measurable clinical or manufacturing benefit is unlikely to support durable pricing.

Lactose-free formulation

A lactose-free tablet is the clearest near-term opportunity. Suitable replacement systems could include microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler. Selection must account for:

• Content uniformity at the 50 mg dose
• Tablet hardness and friability
• Dissolution across relevant pH conditions
• Moisture uptake
• Compatibility with azathioprine
• Powder-flow behavior
• Compression-force requirements

Microcrystalline cellulose can improve compactibility and disintegration control. Mannitol can improve mouthfeel and support chewable or orally disintegrating formats, although its hygroscopicity and compression behavior require assessment. Dibasic calcium phosphate can produce robust tablets but may introduce density and dissolution differences.

A lactose-free product has the strongest commercial logic where prescribers or patients avoid lactose, where a supplier wants a clean-label position, or where a manufacturer seeks a differentiated generic product without changing the active ingredient.

Low-moisture formulation

Moisture control should be treated as a central development objective. Anhydrous excipients, low-moisture processing, high-barrier blister packaging, and controlled humidity manufacturing may improve shelf life and batch consistency.

Potential approaches include:

• Anhydrous diluent systems
• Moisture-barrier aluminum-aluminum blisters
• High-barrier HDPE bottles with desiccant
• Film coatings with low water permeability
• Nitrogen-controlled packaging where justified
• Reduced aqueous exposure during granulation and coating

The commercial value of this strategy is strongest in hot and humid markets, hospital supply chains, and countries where distribution conditions are variable.

Dissolution-enhancing formulation

Azathioprine has limited aqueous solubility. A formulation program should therefore evaluate particle-size reduction, wetting agents, disintegrant optimization, and solid-state control. Candidate excipients may include sodium lauryl sulfate at low levels, poloxamers, crospovidone, croscarmellose sodium, and surfactant-containing granulation systems.

The objective should be faster and more reproducible dissolution, not simply higher apparent solubility. Excessive surfactant use can impair tablet performance, complicate taste, create stability risks, or affect bioequivalence.

A nanosized or amorphous formulation may produce a stronger technical asset, but it also introduces greater complexity around solid-state characterization, physical stability, scale-up, and regulatory comparability.

What formulations are protected by an azathioprine patent strategy?

The active ingredient and original Imuran product are not the main sources of patent value. A new patent position would more likely cover:

1. A specific excipient ratio that produces a defined dissolution or stability profile.
2. A moisture-controlled tablet or packaging combination.
3. A pediatric liquid with demonstrated chemical and microbiological stability.
4. A low-dose or multiparticulate formulation that improves dose flexibility.
5. A taste-masked oral liquid or dispersible tablet.
6. A process using controlled particle size, granulation conditions, or coating parameters.
7. A formulation that reduces degradation products during storage.

A patent application must claim more than a routine substitution of lactose with microcrystalline cellulose. Stronger claims would link composition to measurable performance, such as a defined dissolution profile, impurity limit, stability period, or content-uniformity result.

What is the Orange Book status of Imuran?

The U.S. Orange Book is the relevant source for approved drug products, patent listings, and therapeutic-equivalence information. Imuran has no commercially meaningful remaining new-drug exclusivity. Generic azathioprine products have competed for years, and any listed historical patents would have expired or become irrelevant to current market entry.[3]

For a new azathioprine formulation, the regulatory pathway would generally depend on whether the product is an equivalent generic tablet or a materially different product. A conventional tablet could potentially use an ANDA pathway if all applicable requirements are met. A new dosage form, new route, or clinically differentiated product may require a different application strategy.

When does Imuran lose exclusivity?

Imuran’s exclusivity expired decades ago. The product does not retain the commercial protection associated with a recent NCE approval, pediatric exclusivity period, or active composition-of-matter patent.

Exclusivity category	Current relevance to Imuran
Original composition patent	Expired
Original product patent	Expired
NCE exclusivity	Expired
Pediatric exclusivity	No current protection
Orphan exclusivity	Not applicable to the legacy brand as a general product
Generic entry	Established
Formulation exclusivity	No broad current exclusivity for the historical tablet
Biosimilar exclusivity	Not applicable; azathioprine is a small molecule

There is no biosimilar pathway for azathioprine. Competitive entry occurs through generic drug pathways, not biologic interchangeability or biosimilar substitution.

Which companies are challenging Imuran exclusivity?

The competitive challenge is historical rather than a current Paragraph IV campaign against an active Imuran patent. Generic manufacturers have entered the azathioprine market through abbreviated applications after the expiration of legacy protections.

Potential entrants compete on:

• Wholesale acquisition cost
• Distributor access
• Shortage prevention
• Tablet availability
• Packaging sizes
• Hospital contracts
• Formulation tolerability
• Pediatric supply
• Global registration coverage

A new developer should not base its business case on litigation against the legacy brand. The more relevant IP question is whether a differentiated formulation can obtain protection against later entrants.

What Paragraph IV risks exist for a new azathioprine product?

A developer relying on a new formulation patent could face Paragraph IV certification from a later generic applicant. Risk is higher when the patent claims broad excipient classes or conventional manufacturing steps.

More defensible claims would require:

• Narrow composition ranges
• Defined impurity control
• Demonstrated stability advantages
• Specific dissolution behavior
• Non-obvious manufacturing parameters
• A clinically or commercially meaningful dosage form

The patent estate should include composition, process, packaging, and use claims where supported. Use claims may be limited because many azathioprine indications are established and generic competitors can often design around narrow method-of-use claims.

What commercial opportunities exist for Imuran excipient innovation?

Pediatric oral liquid

A stable oral liquid could address children who cannot swallow tablets and adults requiring dose titration. The formulation must control:

• Chemical degradation in aqueous media
• Uniformity during storage
• Sedimentation or particle-size distribution
• Palatability
• Preservative effectiveness
• Dosing-device accuracy
• Caregiver handling and cytotoxic exposure

A ready-to-use suspension may offer better commercial differentiation than a simple extemporaneous powder. A powder for reconstitution could reduce chemical stability burdens but shift complexity to pharmacy preparation and in-use storage.

Geriatric and dysphagia products

An orally disintegrating tablet, dispersible tablet, or mini-tablet could improve administration. These formats require careful evaluation of taste, dose uniformity, friability, and exposure to caregivers during handling.

An ODT strategy is technically plausible but commercially narrower than a pediatric liquid because azathioprine can require individualized dosing and may be unsuitable for casual manipulation. The product design should minimize powder generation and discourage tablet splitting unless dosing data support it.

Lactose-free and excipient-minimized tablets

A lactose-free, low-allergen, or excipient-minimized product can support hospital formularies and specialty pharmacies. The value proposition is strongest when tied to supply reliability and a documented patient-use benefit.

Hospital and transplant-channel supply

Transplant centers and hospital pharmacies value continuity of supply, predictable tablet strengths, and reliable distribution. A manufacturer can differentiate through:

• Dual-source API procurement
• Safety-stock commitments
• Serialized packaging
• Unit-dose blister presentation
• Robust shortage-management planning
• Hospital-specific pack sizes

The market is price sensitive, so the commercial case depends on operational reliability rather than premium pricing alone.

How does Imuran compare with competing immunosuppressants?

Azathioprine competes with mycophenolate mofetil, mycophenolic acid, corticosteroids, tacrolimus, cyclosporine, and biologic therapies. Its advantages include long clinical history, oral availability, low-cost generic supply, and use in selected pregnancy or transplant-management settings where clinicians may prefer it based on patient-specific considerations. Its disadvantages include marrow toxicity, monitoring requirements, drug interactions, and variable metabolite exposure.

Product	Formulation opportunity	Competitive pressure
Azathioprine	Pediatric liquid, lactose-free tablet, improved stability	High generic price pressure
Mycophenolate mofetil	Delayed-release and suspension products	Strong transplant competition
Tacrolimus	Extended-release and specialty delivery systems	Higher-value therapeutic market
Cyclosporine	Microemulsion and oral liquid	Established formulation differentiation
Methotrexate	Injectable, autoinjector, oral liquid	Competes in autoimmune disease
Biologic immunosuppressants	Pen and infusion delivery systems	Higher cost, different regulatory pathway

Azathioprine is less attractive for a broad premium formulation strategy than tacrolimus or biologic immunosuppressants. It is more attractive for focused lifecycle management, regional supply, pediatric access, and hospital procurement.

What manufacturing and IP barriers affect azathioprine products?

Manufacturing controls are commercially important because azathioprine is a potent immunosuppressive compound with serious toxicity warnings. Facilities should control dust, cross-contamination, operator exposure, and cleaning validation.

Key development barriers include:

• API particle-size variability
• Low-dose content uniformity
• Moisture-related degradation
• Blend segregation
• Coating uniformity
• Cleaning validation
• Occupational exposure control
• Stability-indicating analytical methods
• Extractables and leachables for liquid packaging
• Microbial control for aqueous products

Manufacturing patents may have value when they improve containment, reduce degradation, or enable a reproducible product at commercial scale. Trade secrets around granulation, coating, and packaging can be as important as formal patent claims.

What regulatory status applies to a new Imuran formulation?

A conventional azathioprine tablet intended to match an approved reference product may be eligible for an ANDA, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, manufacturing quality, labeling, and stability.[4]

A new liquid, ODT, injectable, or modified-release product may require a more complex regulatory strategy. The applicant would need to establish the product’s dosage-form performance, stability, safety, and, where applicable, clinical equivalence.

The FDA label also requires careful handling of drug interactions, blood-count monitoring, liver monitoring, and patient-specific pharmacogenetic considerations. A reformulation cannot weaken these warnings or create dosing ambiguity.[1]

What is the revenue opportunity for an azathioprine reformulation?

The conventional generic tablet market is likely to produce modest margins because multiple suppliers compete on price. Revenue exposure is therefore concentrated in differentiated segments:

1. Pediatric and dysphagia products with limited direct competition.
2. Hospital and transplant-center supply contracts.
3. Lactose-free or excipient-reduced tablets.
4. Regional markets with limited local supply.
5. Stable oral liquids for specialty pharmacies.
6. Packaging and presentation improvements that reduce dispensing errors.

A premium price is more defensible for a product that solves a measurable access or stability problem. A standard 50 mg generic tablet with a cosmetic excipient change has limited pricing power.

How strong is the patent estate for Imuran?

The legacy Imuran patent estate is weak for current commercial protection because the core rights have expired. A new developer can still create a moderate formulation estate if it generates comparative data and claims a specific technical effect.

IP category	Strength for legacy Imuran	Opportunity for a new product
Composition of matter	None	None
Conventional 50 mg tablet	Low	Low unless technically differentiated
Lactose-free tablet	Low by itself	Moderate with performance-linked claims
Pediatric liquid	None for legacy product	Moderate to strong if stability and taste are demonstrated
Moisture-barrier packaging	None for legacy product	Moderate
Process control	Low for legacy product	Moderate if non-obvious and scalable
Method of use	Limited	Narrow, indication-specific opportunities
Trade secrets	Manufacturer-specific	Meaningful for process and supply reliability

Key Takeaways

• Imuran is azathioprine, a legacy immunosuppressant with expired core exclusivity.
• The historical tablet uses a conventional lactose, maize starch, magnesium stearate, and film-coating system.
• The strongest excipient opportunity is a lactose-free, moisture-controlled tablet with demonstrated dissolution and stability performance.
• Pediatric oral liquids and dysphagia-friendly products offer greater differentiation than a standard generic tablet.
• There is no biosimilar risk because azathioprine is a small molecule.
• Paragraph IV litigation against legacy Imuran patents is not the central commercial issue; new formulation patents would create the relevant litigation exposure.
• Manufacturing containment, content uniformity, stability, and supply reliability are major barriers.
• Revenue potential is greater in specialty, hospital, pediatric, and regional supply channels than in undifferentiated retail generics.

FAQs

Is Imuran still protected by a patent?

No. The original azathioprine and Imuran protections expired long ago. Current commercial protection would need to come from a new formulation, process, packaging, or dosage-form patent.

Can azathioprine be formulated without lactose?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed excipient system. The replacement must preserve content uniformity, dissolution, stability, and tablet performance.

Is there a commercial opportunity for liquid azathioprine?

Yes. A stable, palatable, accurately dosed oral liquid could serve pediatric patients, patients with dysphagia, and specialty pharmacies. Chemical stability and caregiver handling are the principal development challenges.

Does azathioprine have biosimilar competition?

No. Azathioprine is a chemically synthesized small molecule. Competition occurs through generic-drug pathways rather than biosimilar applications.

Which excipient strategy offers the best patent potential?

A formulation that combines a defined excipient system with demonstrated stability, dissolution, impurity control, or dose-uniformity performance has better patent potential than a routine filler substitution.

References

1. U.S. Food and Drug Administration. (2023). Imuran (azathioprine) tablets: Prescribing information.
2. DailyMed. (n.d.). Imuran-azathioprine tablet, film coated: Inactive ingredients and labeling. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition.
4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of abbreviated new drug applications.